Division of Hematology/Oncology, Department of Internal Medicine, University of Cincinnati College of Medicine, 3125 Eden Ave., Rm 1316, Cincinnati, OH, 45267, USA.
Division of Digestive Diseases, Department of Internal Medicine, University of Cincinnati College of Medicine, Cincinnati, OH, USA.
BMC Gastroenterol. 2023 Mar 9;23(1):65. doi: 10.1186/s12876-023-02695-6.
Current quantitative approaches to assess chronic liver disease (CLD) severity have limitations. Further, portal vein thrombosis (PVT) pre-liver transplant (LT) is a major contributor to morbidity in CLD; the means of detecting and/or predicting PVT are limited. We sought to explore whether plasma coagulation factor activity levels can serve as a substitute for prothrombin time/international normalized ratio (PT/INR) in the Model for End-stage Liver Disease (MELD), and/or help assess the risk of PVT.
Plasma activity levels of Factor V (FV), Factor VIII (FVIII), Protein C (PC), and Protein S (PS) and the concentrations of D-dimer, sP-selectin, and asTF were assessed in two cohorts of CLD patients (ambulatory, n = 42; LT, n = 43).
FV and PC activity levels strongly correlated with MELD scores, which enabled the development of a novel scoring system based on multiple linear regressions of the correlations of FV and PC activity with MELD-Na that substitutes PT/INR. Six-month and 1-year follow-up revealed that our novel approach was non-inferior to MELD-Na at predicting mortality. A significant inverse correlation between FVIII activity levels and PVT was found in the LT cohort (p = 0.010); FV and PS activity levels were in-trend (p = 0.069, p = 0.064). We developed a logistic regression-based compensation score to identify patients at risk of PVT.
We demonstrate that FV and PC activity levels may be used to replace PT/INR in MELD scoring. We also show the potential of using the combination of FV, FVIII, and PS activity levels to assess the risk of PVT in CLD.
目前评估慢性肝病(CLD)严重程度的定量方法存在局限性。此外,肝移植(LT)前门静脉血栓形成(PVT)是 CLD 发病率的主要原因;检测和/或预测 PVT 的手段有限。我们试图探讨血浆凝血因子活性水平是否可以替代凝血酶原时间/国际标准化比值(PT/INR)在终末期肝病模型(MELD)中,并/或有助于评估 PVT 的风险。
在两个 CLD 患者队列(门诊,n=42;LT,n=43)中评估了因子 V(FV)、因子 VIII(FVIII)、蛋白 C(PC)和蛋白 S(PS)的血浆活性水平以及 D-二聚体、sP-选择素和 asTF 的浓度。
FV 和 PC 活性水平与 MELD 评分强烈相关,这使得能够根据 FV 和 PC 活性与 MELD-Na 的相关性进行多元线性回归来开发一种新的评分系统,以替代 PT/INR。6 个月和 1 年的随访结果表明,我们的新方法在预测死亡率方面不劣于 MELD-Na。在 LT 队列中发现 FVIII 活性水平与 PVT 呈显著负相关(p=0.010);FV 和 PS 活性水平呈趋势(p=0.069,p=0.064)。我们开发了一种基于逻辑回归的补偿评分来识别有 PVT 风险的患者。
我们证明 FV 和 PC 活性水平可用于替代 MELD 评分中的 PT/INR。我们还表明,使用 FV、FVIII 和 PS 活性水平的组合来评估 CLD 中 PVT 的风险具有潜力。